Terapia combinada con antibióticos: un enfoque ampliamente utilizado pero poco comprendido
Barra lateral del artículo
Contenido principal del artículo
Resumen
La terapia combinada con antibióticos es ampliamente utilizada en la práctica clínica, aunque su aplicación frecuentemente carece de un entendimiento profundo de sus fundamentos farmacológicos. Esta revisión analiza críticamente los principios, beneficios y limitaciones de esta estrategia, integrando información de estudios in vitro, modelos animales y literatura clínica relevante. Para facilitar el análisis, se utilizó Elicit como herramienta de apoyo en la organización de los estudios seleccionados. Aunque estas combinaciones pueden ampliar el espectro antimicrobiano, mejorar la actividad bactericida o prevenir la aparición de resistencia, también pueden presentar interacciones aditivas o antagónicas que limitan su eficacia clínica. Se concluye que el uso racional de combinaciones antibióticas debe basarse en objetivos terapéuticos bien definidos y en evidencia científica sólida, más allá de la intuición empírica, con el fin de optimizar los resultados clínicos y enfrentar con precisión la resistencia antimicrobiana.
Detalles del artículo
Citas
Gómara M, Ramón-García S. The FICI paradigm: Correcting flaws in antimicrobial in vitro synergy screens at their inception. Biochem Pharmacol. mayo de 2019;163:299-307. https://doi.org/10.1016/j.bcp.2019.03.001
Tamma PD, Cosgrove SE, Maragakis LL. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. Clin Microbiol Rev. julio de 2012;25(3):450-70. https://doi.org/10.1128/CMR.05041-11
Spellberg B. Principles of Antiinfective Therapy. En: Blaser M Martin J, Cohen M Jeffrey I, Holland M Steven M, Doi P Yohei, MD, Falsey M Ann R, Garrett P Wendy S, MD, et al., editores. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases [Internet]. Tenth Edition. 2026. p. 218-228.e3. Disponible en: https://www.clinicalkey.es/#!/content/3-s2.0-B9780323934992000177
Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. marzo de 2019;17(3):141-55. https://doi.org/10.1038/s41579-018-0141-x
Hunter TH. Use of streptomycin in the treatment of bacterial endocarditis. Am J Med. mayo de 1947;2(5):436-42. https://doi.org/10.1016/0002-9343(47)90088-0
Jawetz E, Gunnison JB, Speck RS. Antibiotic Synergism and Antagonism. N Engl J Med. 20 de diciembre de 1951;245(25):966-8. https://doi.org/10.1056/NEJM195112202452503
TREATMENT of pulmonary tuberculosis with streptomycin and paraaminosalicylic acid; a Medical Research Council investigation. Br Med J. 11 de noviembre de 1950;2(4688):1073-85. https://doi.org/10.1136/bmj.2.4688.1073
Lorian V, Fodor G. Technique for Determining the Bactericidal Effect of Drug Combinations. Antimicrob Agents Chemother. junio de 1974;5(6):630-3. https://doi.org/10.1128/AAC.5.6.630
Pak TR, Young J, McKenna CS, Agan A, DelloStritto L, Filbin MR, et al. Risk of Misleading Conclusions in Observational Studies of Time-to-Antibiotics and Mortality in Suspected Sepsis. Clin Infect Dis. 30 de noviembre de 2023;77(11):1534-43. https://doi.org/10.1093/cid/ciad450
Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. diciembre de 2015;19(1):63. https://doi.org/10.1186/s13054-015-0795-y
Flórez Riaño AF, Rojas Castro OJ, Ospina S, Ramírez-Sánchez IC. Association between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy. J Infect Chemother. Febrero de 2025;31(2):102538. https://doi.org/10.1016/j.jiac.2024.10.006
Karlsen OE, Borgen P, Bragnes B, Figved W, Grogaard B, Rydinge J, et al. Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial. J Orthop Surg. diciembre de 2020;15(1):365. https://doi.org/10.1186/s13018-020-01877-2
Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase- producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 21 de noviembre de 2018;7(1):142. https://doi.org/10.1186/s13756-018-0435-9
Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL. A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clin Infect Dis. 2 de julio de 2018;67(2):303-9. https://doi.org/10.1093/cid/ciy064
Jimenez-Toro I, Rodriguez CA, Zuluaga AF, Otalvaro JD, Vesga O. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. Chang YF, editor. PLOS ONE. 8 de diciembre de 2020;15(12):e0243365. https://doi.org/10.1371/journal.pone.0243365
Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother. septiembre de 1995;39(9):1984-7. https://doi.org/10.1128/AAC.39.9.1984
Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Peña C, De Alarcon A, et al. Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis. Clin Infect Dis. 1 de mayo de 2013;56(9):1261-8. https://doi.org/10.1093/cid/cit052
Heineman HS, Lofton WM. Unpredictable Response of Pseudomonas aeruginosa to Synergistic Antibiotic Combinations In Vitro. Antimicrob Agents Chemother. mayo de 1978;13(5):827-31. https://doi.org/10.1128/AAC.13.5.827
Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, et al. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. J Antimicrob Chemother. 15 de julio de 2021;76(8):2172-81. https://doi.org/10.1093/jac/dkab134
Delgado V, Ajmone Marsan N, De Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 14 de octubre de 2023;44(39):3948-4042.
Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. mayo de 2021;57(5):106344. https://doi.org/10.1016/j.ijantimicag.2021.106344
Barriere SL. Bacterial Resistance to B-Lactams, and Its Prevention With Combination Antimicrobial Therapy. Pharmacother J Hum Pharmacol Drug Ther. 10 de septiembre de 1992;12(5):397-402. https://doi.org/10.1002/j.1875-9114.1992.tb04478.x
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 7 de agosto de 2024;ciae403. https://doi.org/10.1093/cid/ciae403
Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang KC, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primer. 24 de marzo de 2024;10(1):22. https://doi.org/10.1038/s41572-024-00504-2
Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 1995;15(3):279-91. https://doi.org/10.1002/j.1875-9114.1995.tb04366.x
Holland P, Jahnke N. Single versus combination intravenous antipseudomonal antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 23 de junio de 2021;6(6):CD002007. https://doi.org/10.1002/14651858.CD002007.pub5
Eliopoulos' CT. Antibiotic Combinations: Should They Be Tested? CLIN MICROBIOL REV. 1988;1. https://doi.org/10.1128/CMR.1.2.139
Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. N Engl J Med. 18 de octubre de 2012;367(16):1508-18. https://doi.org/10.1056/NEJMoa1201964
Babiker A, Li X, Lai YL, Strich JR, Warner S, Sarzynski S, et al. Effectiveness of adjunctive clindamycin in B-lactam antibiotic-treated patients with invasive B-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis. mayo de 2021;21(5):697-710. https://doi.org/10.1016/S1473-3099(20)30523-5
Karakonstantis S, Ioannou P, Kofteridis DD. In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations. Infection. junio de 2022;50(3):569-81. https://doi.org/10.1007/s15010-021-01748-w
Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. The Lancet. septiembre de 2024;404(10459):1199-226.
Wang Y, Li H, Xie X, Wu X, Li X, Zhao Z, et al. In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli. J Glob Antimicrob Resist. marzo de 2020;20:351-9. https://doi.org/10.1016/j.jgar.2019.09.013
Ma XL, Guo YZ, Wu YM, Gong WT, Sun J, Huang Z. In vivo bactericidal effect of colistin-linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia. Sci Rep. 15 de octubre de 2020;10(1):17518. https://doi.org/10.1038/s41598-020-74503-0
Ribes S, Pachón-Ibañez ME, Domínguez MA, Fernandez R, Tubau F, Ariza J, et al. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. Eur J Clin Microbiol Infect Dis. Noviembre de 2010;29(11):1361-7. https://doi.org/10.1007/s10096-010-1007-y
Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. agosto de 1993;37(8):1630-6. https://doi.org/10.1128/AAC.37.8.1630
Domenech A, Ribes S, Cabellos C, Taberner F, Tubau F, Domínguez MA, et al. Experimental study on the efficacy of combinations of glycopeptides and B-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother. 1 de octubre de 2005;56(4):709-16. https://doi.org/10.1093/jac/dki294
Kaouah Z, Buyck JM, Pichon M, Burucoa C, Prouvensier L, Moreau J, et al. In vitro efficacy of combinations of antibiotics used in clinical practice on clinical isolates of Helicobacter pylori. Helicobacter. mayo de 2024;29(3):e13081. https://doi.org/10.1111/hel.13081
Wei W, Yang H, Hu L, Ye Y, Li J. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii : In vitro and in a Galleria mellonella model. J Microbiol Immunol Infect. diciembre de 2017;50(6):821-30. https://doi.org/10.1016/j.jmii.2015.10.010
Robertson GT, Scherman MS, Bruhn DF, Liu J, Hastings C, McNeil MR, et al. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. J Antimicrob Chemother. 20 de diciembre de 2016;dkw467. https://doi.org/10.1093/jac/dkw467
Yu Y, Walsh TR, Yang RS, Zheng M, Wei MC, Tyrrell JM, et al. Novel partners with colistin to increase its in vivo therapeutic effectiveness and prevent the occurrence of colistin resistance in NDM- and MCRco-producing Escherichia coli in a murine infection model. J Antimicrob Chemother [Internet]. 20 de octubre de 2018 [citado 11 de marzo de 2025]; Disponible en: https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dky413/5139795 https://doi.org/10.1093/jac/dky413
Lorian V, editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. 889 p.
Tang HJ, Chen CC, Lai CC, Zhang CC, Weng TC, Chiu YH, et al. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect. febrero de 2018;51(1):76-81. https://doi.org/10.1016/j.jmii.2016.04.009
Bax HI, Bakker-Woudenberg IAJM, De Vogel CP, Van Der Meijden A, Verbon A, De Steenwinkel JEM. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of antituberculosis drugs. Tuberculosis. julio de 2017;105:80-5. https://doi.org/10.1016/j.tube.2017.04.010
Kebriaei R, Rice SA, Singh KV, Stamper KC, Dinh AQ, Rios R, et al. Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with - Lactams against Daptomycin - Susceptible Enterococcus faecium Harboring LiaSR Substitutions.
Moellering RC, Medoff G, Leech I, Wennersten C, Kunz LJ. Antibiotic Synergism Against Listeria monocytogenes. Antimicrob Agents Chemother. enero de 1972;1(1):30-4. https://doi.org/10.1128/AAC.1.1.30
Li J, Yang X, Chen L, Duan X, Jiang Z. In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii : A Systematic Review and Meta-Analysis. Microb Drug Resist. diciembre de 2017;23(8):982-93. https://doi.org/10.1089/mdr.2016.0279
Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, et al. Synergistic Activity of Colistin and Rifampin Combination against MultidrugResistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/ Pharmacodynamic Model. Antimicrob Agents Chemother. agosto de 2013;57(8):3738-45. https://doi.org/10.1128/AAC.00703-13
Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents. julio de 2009;34(1):8.e1-8.e9. https://doi.org/10.1016/j.ijantimicag.2008.11.006
White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. agosto de 1996;40(8):1914-8. https://doi.org/10.1128/AAC.40.8.1914
Oka' S, Goto' M, Kaji' Y, Kimara' S, Matsuda K, Asahi Y, et al. Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus.
Sanderink D, Cassisa V, Chenouard R, Mahieu R, Kempf M, Dubee V, et al. Colistin-Glycopeptide Combinations Against Multidrug-Resistant Acinetobacter Baumannii in a Mouse Model of Pneumonia. Future Microbiol. mayo de 2019;14(7):581-6. https://doi.org/10.2217/fmb-2019-0022
Norden CW. Experimental Osteomyelitis. IV. Therapeutic Trials with Rifampin Alone and in Combination with Gentamicin, Sisomicin, and Cephalothin. J Infect Dis. 1 de noviembre de 1975;132(5):493-9. https://doi.org/10.1093/infdis/132.5.493
Vouillamoz J, Moreillon P, Giddey M, Entenza JM. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. febrero de 2008;61(2):371-4. https://doi.org/10.1093/jac/dkm459
Zhuang L, Sy SKB, Xia H, Singh RP, Mulder MB, Liu C, et al. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamics model. Int J Antimicrob Agents. febrero de 2015;45(2):151-60. https://doi.org/10.1016/j.ijantimicag.2014.09.017
Perea EJ, Clavijo E, Nogales MC, Luque IG. Interaction of aminoglycosides and cephalosporins against Pseudomonas aeruginosa . Correlation between interaction index and killing curve. J Antimicrob Chemother. 1988;22(2):175-83. https://doi.org/10.1093/jac/22.2.175
Jawetz E, Gunnison JB, Coleman VR. Observations on the Mode of Action of Antibiotic Synergism and Antagonism. J Gen Microbiol. 1 de abril de 1954;10(2):191-8. https://doi.org/10.1099/00221287-10-2-191
Ocampo PS, Lazar V, Papp B, Arnoldini M, Abel Zur Wiesch P, Busa-Fekete R, et al. Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent. Antimicrob Agents Chemother. agosto de 2014;58(8):4573-82. https://doi.org/10.1128/AAC.02463-14
Lepper MH. TREATMENT OF PNEUMOCOCCIC MENINGITIS WITH PENICILLIN COMPARED WITH PENICILLIN PLUS AUREOMYCIN: Studies Including Observations on an Apparent Antagonism Between Penicillin and Aureomycin. AMA Arch Intern Med. 1 de octubre de 1951;88(4):489. https://doi.org/10.1001/archinte.1951.03810100073006
Gil-Gil T, Berryhill BA. Antibiotic killing of drug-induced bacteriostatic cells. Uhlemann AC, editor. Antimicrob Agents Chemother. 26 de marzo de 2025;e00156-25. https://doi.org/10.1101/2024.09.06.611640
De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial. Ann Intern Med. 15 de mayo de 1994;120(10):834-44. https://doi.org/10.7326/0003-4819-120-10-199405150-00004
Pan K, Li R, Li Y, Ding X, Li X, Lv Q. Vancomycin combined with piperacillin/ tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis. J Antimicrob Chemother. 3 de enero de 2025;80(1):47-58. https://doi.org/10.1093/jac/dkae410
Jimenez-Toro I, Rodriguez CA, Zuluaga AF, Otalvaro JD, Perez-Madrid H, Vesga O. Pharmacokinetic/Pharmacodynamic Index Linked to In Vivo Efficacy of the Ampicillin-Ceftriaxone Combination against Enterococcus faecalis. Antimicrob Agents Chemother. 16 de febrero de 2023;67(2):e00966-22. https://doi.org/10.1128/aac.00966-22
Zuluaga AF, Vesga O. Aportes del modelo en ratón neutropénico de infección del muslo al conocimiento sobre la farmacología de antibióticos.
Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. abril de 2002;19(4):261-8. https://doi.org/10.1016/S0924-8579(02)00022-5
Gavalda J, Torres C, Tenorio C, Lopez P, Zaragoza M, Capdevila JA, et al. Efficacy of Ampicillin plus Ceftriaxone in Treatment of Experimental Endocarditis Due to Enterococcus faecalis Strains Highly Resistant to Aminoglycosides. Antimicrob Agents Chemother. marzo de 1999;43(3):639-46. https://doi.org/10.1128/AAC.43.3.639
Zhao M, Lepak AJ, Andes DR. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem. diciembre de 2016;24(24):6390-400. https://doi.org/10.1016/j.bmc.2016.11.008
Jimenez Toro I, Rodriguez CA, Zuluaga AF. Eficacia de las combinaciones antimicrobianas para el tratamiento de infecciones enterocócicas: una revisión crítica. Rev Chil Infectol. octubre de 2019;36(5):556-64. https://doi.org/10.4067/S0716-10182019000500556
Parveen N, Sikander RI, Zeeshan M, Muneeb Ali S, Hassan M. Comparison Between the Combination Therapy in Terms of Therapeutic Effectiveness and Anti-Microbial Efficacy in Extensive Drug-Resistant Acinetobacter Baumannii Infections. Life Sci. 4 de julio de 2023;4(3):6. https://doi.org/10.37185/LnS.1.1.312
Story-Roller E, Maggioncalda EC, Lamichhane G. Synergistic Efficacy of B-Lactam Combinations against Mycobacterium abscessus Pulmonary Infection in Mice. Antimicrob Agents Chemother. agosto de 2019;63(8):e00614-19. https://doi.org/10.1128/AAC.00614-19
Andrejak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations. Antimicrob Agents Chemother. abril de 2015;59(4):2129-35. https://doi.org/10.1128/AAC.04841-14
Skinner K, Sandoe JAT, Rajendran R, Ramage G, Lang S. Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model. Int J Antimicrob Agents. abril de 2017;49(4):507-11. https://doi.org/10.1016/j.ijantimicag.2016.12.006
Lee M, Abbey T, Biagi M, Wenzler E. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-B-lactamase- producing Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. Enero de 2021;99(1):115227. https://doi.org/10.1016/j.diagmicrobio.2020.115227
Mularoni A, Mezzatesta ML, Pilato M, Medaglia AA, Cervo A, Bongiorno D, et al. Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis. Int J Infect Dis. julio de 2021;108:510-2. https://doi.org/10.1016/j.ijid.2021.05.085
Charlier C, Perrodeau E, Leclercq A, Cazenave B, Pilmis B, Henry B, et al. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infect Dis. mayo de 2017;17(5):510-9.
Wang L, Tong X, Huang J, Zhang L, Wang D, Wu M, et al. Triple Versus Double Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Enterobacteriaceae: A Systematic Review and Meta-Analysis. Front Pharmacol. 30 de enero de 2020;10:1673. https://doi.org/10.3389/fphar.2019.01673
Kim SH, Kim HM, Chung DR, Ko JH, Huh K, Cho SY, et al. Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa : a time-kill assay. J Antimicrob Chemother. 3 de marzo de 2025;80(3):738-45. https://doi.org/10.1093/jac/dkae466
Lagerback P, Khine WWT, Giske CG, Tangden T. Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments. J Antimicrob Chemother. agosto de 2016;71(8):2321-5. https://doi.org/10.1093/jac/dkw213
Couet W. Pharmacokinetics/pharmacodynamics characterization of combined antimicrobial agents: a real challenge and an urgent need. Clin Microbiol Infect. julio de 2018;24(7):687-8. https://doi.org/10.1016/j.cmi.2018.03.047
Sy SKB, Derendorf H. Experimental design and modelling approach to evaluate efficacy of B-lactam/B-lactamase inhibitor combinations. Clin Microbiol Infect. julio de 2018;24(7):707-15. https://doi.org/10.1016/j.cmi.2017.07.020
Assefa GM, Roberts JA, Mohammed SA, Sime FB. What are the optimal pharmacokinetic/pharmacodynamic targets for B-lactamase inhibitors? Asystematic review. J Antimicrob Chemother. 2 de mayo de 2024;79(5):946-58. https://doi.org/10.1093/jac/dkae058